Idogen publishes interim report for 1 January – 31 December 2021
Idogen AB's interim report for January to December 2021 is available on the company's website https://idogen.com/en/investors/financial-reports/
Fourth quarter (October- December 2021)
• Other operating income amounted to KSEK 3,335 (1,949)
• Operating loss was KSEK -13,552 (-7,449)
• Loss for the quarter totalled KSEK -13,529 (-7,897)
• Cash flow from operating activities was KSEK -15,074 (-10,428)
• Loss per share before dilution was SEK -0.61 (-0.74). Loss per share after dilution was SEK -0.61 (-0.74)
• The proposed dividend is SEK 0.00/share (0.00)
Period (January-December 2021)
• Other operating income amounted to KSEK 13,915 (8,113)
• Operating loss was KSEK -38,965 (-26,153)
• Loss for the period totalled KSEK -38, 854 (-26,822)
• Cash flow from operating activities was KSEK -40,190 (-28,081)
• Loss per share before dilution was SEK -2.02 (-3.32). Loss per share after dilution was SEK -2.02 (-3.32)
Significant events in the fourth quarter
• Idogen generated proceeds of MSEK 9.9 before issue costs when shares were subscribed for with the support of subscription warrants (TO4).
• Idogen has successfully completed the optimization and qualification of the manufacturing process in compliance with GMP, for the first clinical study with its tolerogenic cell therapy IDO 8
• Idogen has submitted an application to the Swedish Medical Products Agency for the start of a clinical phase 1/2a study to obtain safety data and signals on the effect in hemophilia patients with antibodies to their treatment Factor VIII
• Idogen’s Board of Directors proposes a rights issue that will provide the company with approximately MSEK 41 after issue costs
• Idogen’s board convenes an extraordinary general meeting on January 20, 2022, to decide on a rights issue
Significant events during the period
• Idogen initiated new activities in order to maximize the effect of the tolerogenic cell therapy IDO 8 before the start of the first clinical trial.
• The COVID-19 pandemic affected work at the Radboud University Medical Center.
• Idogen appointed highly reputable scientific advisors in transplantation.
• Additional payment of MSEK 3 is made from the EU Commission for the company’s project within the Horizon 2020 programme
• The European Patent Office (EPO) granted a European patent to protect the company’s tolerogenic cell therapy.
Significant events after the end of the period
• Idogen submits an application for clinical trial with IDO 8 to the Norwegian Medicines Agency, NoMA.
• The no other significant events occurred after the end of the period that affected the results or financial position.
For further information, please contact:
Anders Karlsson, CEO, Idogen AB
Phone: +46 (0)70 918 00 10
Email: anders.karlsson@idogen.com
Certified Adviser:
Erik Penser Bank AB, Box 7405, 103 91 Stockholm
Phone: +46 (0)8-463 80 00
Email: certifiedadviser@penser.se
The information was submitted for publication, through the agency of the contact persons set out above, on January 19, 2022 at 08:07 CET.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care. More information about Idogen is available via https://www.idogen.com